A unit of Johnson & Johnson announced July 18 that it has received Food and Drug Administration approval for use of Simponi ARIA (golimumab) for infusion for adults with moderately to severely active rheumatoid arthritis, in combination with methotrexate.
Janssen Biotech Inc. said that Simponi ARIA, the only fully human anti-tumor necrosis factor (TNF)-alpha infusible therapy, has been shown to significantly improve signs and symptoms and physical function, and inhibit the progression of structural damage.
Janssen, which is based in Horsham, Pa., said that the Simponi ARIA dose regimen is 2 milligrams/kilogram given as an intravenous infusion at weeks zero ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.